Emirodatamab

N/A

Report date: 2026/03/19 16:47:17

Base Information

Drug NameEmirodatamab

Drug Alias NameFLT3 BiTEFLT3 HLE BITEanti-FLT3 x anti-CD3 BiTE (Amgen)FLT3/CD3-directed bispecific T-cell engager antibody (Amgen)AMG-427

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > T cell engagers

Mechanisms of ActionTyrosine-protein kinase receptor FLT3 inhibitorsT cell surface glycoprotein CD3 inhibitors

TargetsT cell surface glycoprotein CD3Tyrosine-protein kinase receptor FLT3

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited StatesAustralia +[7]

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesAmgen Inc

China Registration ClassN/A

Develop Information

Active CompaniesBeOne Medicines Ltd

Inactive CompaniesAmgen Inc

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A